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ABSTRACT Human epidermal growth factor receptor 2 (HER2) overexpression has been associated with increased in-
vasiveness in mammalian breast cancer cell lines, but the effects of overexpression on key underlying cell migration properties
such as translational speed and directional persistence are not understood. Moreover, the differential effect of HER2 activation
through heterodimerization with epidermal growth factor receptor versus human epidermal growth factor receptor 3 (HER3) on cell
speedand persistence has not been studied. To investigate these issues, wedeveloped a high-throughput wound closure assay in
which individual cell locomotion and wound closure kinetics were quantiﬁed in humanmammary epithelial cells with varying levels
of HER2 under epidermal growth factor or heregulin (a HER3 ligand) stimulation. Increasing levels of HER2 elevated wound
closurewith closure kinetics dependent on ligand treatment. Cell speed increasedwith HER2 levels under epidermal growth factor
treatment, but decreased under heregulin treatment. In contrast, directional persistence increased with HER2 levels under both
ligand treatments. Increasing persistence quantitatively accounted for observed elevated wound closure, as measured by the
effective diffusion of the cells. Taken together, the data show that the HER2 overexpression mediates cell migration through
differential control of translational speed and directional persistence dependent on epidermal growth factor receptor-HER2 versus
HER2-HER3 heterodimerization. Observed consistent increases in persistence associated with HER2 overexpression indicate a
prospective mechanism for invasiveness previously documented in HER2-overexpressing human breast tumors.
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Human epidermal growth factor receptor 2 (HER2) is over-
expressed in 20–30% of breast cancers and correlates with
poor prognosis and increased metastasis (1). HER2 belongs
to the ErbB or HER family of receptors (comprised of HER1/
EGFR, HER2, HER3, and HER4) and can be activated through
concentration-dependent homodimerization or ligand-driven
heterodimerization. Epidermal growth factor (EGF) and here-
gulin (HRG), two ErbB family ligands implicated in cancer
progression, bind HER1 and HER3, respectively, to induce
the activation of HER2 through heterodimerization (2). Be-
cause of HER2’s role in breast cancer metastasis, a number of
groups have investigated the effect of HER2 expression on
aspects of cell motility, demonstrating that activation by
EGF, HRG, or homodimerization leads to increased invasion
and motility in breast cancer cell lines (3–5). In addition,
these and other studies have implicated various downstream
signaling molecules as effectors of HER2-increased motility.
Primarily because many of these studies relied on invasion
assays, however, there is little known about how HER2 overe-
xpression affects cell migration parameters such as cell speed
and persistence. Prior study of primary ductal breast carci-
noma cells revealed that groups of cells tend to detach from
primary tumor lesions and move away in a highly polarized
and directionally persistent manner, indicating that the control
of directional persistence may be distinct in highly motile
breast cancer cells, such as those with HER2 overexpression
(6). In addition, increased directional persistence has been
identiﬁed as a hallmark of cell migration in highly invasive
tumors, such as neuroepithelial tumors (7). Distinct signaling
and biophysical mechanisms controlling directional persis-
tence versus random motility have also been identiﬁed in
recent studies (8–10). Thus, a more in-depth study of HER2’s
effect on cell migration, speed, and persistence could poten-
tially serve two purposes: 1), to connect HER2 overexpression
with persistent movement shown to be important in cancer
systems; and 2), to provide a context within which to un-
derstand previously identiﬁed HER2-associated downstream
signals by linking them to pathways that regulate direction-
ally persistent migration.
We examined cell migration in a human mammary epithelial
cell line. Two clones of the cell line, parental (with 200,000
EGFR, 20,000 HER2, and 20,000 HER3) and 24H (200,000
EGFR, 600,000 HER2, and 30,000 HER3), were studied
in the presence of EGF (100 ng/ml), HRG (80 ng/ml), or
serum-free media. Cell migration was tracked using a high-
throughput 96-well migration assay that we developed for
the rapid screening of cell motility. The movement of
epithelial monolayers and the motility of hundreds of indi-
vidual cells in monolayers were rapidly screened, generating
time-resolved population-level statistics for all treatment
conditions during one 15-h time course (Supplementary Fig. 1
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and Supplementary Methods). This presages future assay ap-
plication to drug-based screens designed to rapidly explore
the biochemical basis of cell migration.
Increasing HER2 levels from 20,000 to 600,000 increased
wound closure across all treatment conditions (Fig. 1, A–D).
Absolute levels of wound closure differed depending on treat-
ment condition, with EGF-treated cells being the most motile
followed by HRG-treated cells under both low and high HER2
expression (Fig. 1 A). EGF-treated 24H cells exhibited the
most rapid closure, completely sealing the wound in;6 h, and
EGF treatment showed the most responsiveness to HER2
overexpression as measured by the difference in closure be-
tween parental and 24H cells at 15 h. Interestingly, HER2
overexpression caused elevated closure even in the absence of
ligand, presumably due to low levels of autocrine production
or concentration-dependent homodimerization.
Detailed inspection of wound-closure kinetics demon-
strates time-dependent control of migration differing across
treatment conditions. For instance, in the presence of HRG,
HER2 overexpression increased wound closure signiﬁcantly
only after the ﬁrst 3.5 h, with both parental and 24H wounds
measuring;68% of the original area before separation (p.
0.9; means are the same). In contrast, serum-free and EGF-
treated 24H cells close more wound than similarly treated
parentals at 3.5 h (p, 0.01), demonstrating that HRG exerts
temporally distinct control ofmigration.Movement after 3.5 h
differentiates the HRG-treated cells, with 24H cells closing
;25% more normalized wound area than parentals at 15 h.
Another interesting kinetic trend is the cessation of wound
closure that occurs at early times under certain conditions. For
instance, HRG-treated 24H cells close the wound throughout
the duration of the experiment, but parental cells stop their
movement after;5h (Fig. 1D). Interestingly, even after wound
closure has stopped, HRG-treated cells continue to move in
the monolayer, suggesting that cell movement perpendic-
ular to the wound front is controlled separately from cell
movement within the monolayer and parallel to the wound
front (data not shown). EGF-treated parental cells exhibit
similar behavior as do both parental and 24H cells in serum-
free conditions. The time at which wound closure stops varies
from ;2 to 6 h depending on treatment conditions, but cell
movement in the monolayer and parallel to the wound
continues in all cases. These data are consistent with wound
closure observations from other groups, and although the
mechanistic basis of this ‘‘stopping’’ behavior is not fully
understood, it is clear that HER2 overexpression in the
context of HRG or EGF treatment provides necessary
information to overcome the signals governing the termina-
tion ofwound closure before thewound is sealed (11). Fig. 1A
also reveals that cells under all treatment conditions close
similar wound areas at early times (21–29% wound area
closed under all conditions at 1.5 h). This suggests that early
wound closure is primarily governed bymechanical induction
and associated start signals that operate independently of
ligand/receptor conditions (Supplementary Fig. 2).
We considered whether the demonstrated differences in
migration might arise from changes in cell speed, directional
persistence, or both. We wondered further whether cells use
these twomigration ‘‘levers’’ in a similar or differentmanner to
increase migration under different ligand treatments. To ex-
plore these questions, we tracked the wound closure response
of ﬂuorescent cells diluted in unlabeled cells. Dilution allowed
for more accurate cell tracking within the monolayer (see Sup-
plementary Methods). We then calculated the mean-squared
displacement for each cell trajectory and ﬁt it to the following
equation:
Æd2ðtÞæ ¼ 2S2P½t  Pð1 et=PÞ; (1)
where S is cell speed and P is cell directional persistence
(12). Data demonstrated that although HER2 overexpression
increased wound closure for all ligand conditions studied, it
did not necessarily increase cell speed. Indeed, when HER2
was overexpressed, serum-free cell speed did not differ and
HRG-treated cells exhibited slightly decreased speed (Fig.
2 A). EGF-treated cells, however, increased cell speed with
HER2 overexpression (Fig. 2 A). The magnitude of cell
speed was similar between HRG treatment and serum-free
conditions, but signiﬁcantly higher for EGF-treated cells. In
contrast to cell speed data, HER2 overexpression increased
directional persistence across all treatments. EGF treatment
stimulated the highest degree of persistence, whereas HRG
treatment induced the largest change between low and high
FIGURE 1 HER2 overexpression increases cell migration. Nor-
malized wound area as a function of time for (A) parental and 24H
cells under EGF (100 ng/ml), HRG (80 ng/ml), or serum-free treat-
ment; (B) parental and 24H cells in serum-free conditions; (C) EGF-
treated parental and 24H cells; and (D) HRG-treated parental or 24H
cells. All time points shown6 SE after time averaging (see Supple-
mentary Methods). For raw data time courses see Supplementary
Fig. 3.
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HER2 conditions. Cell speed and persistence data together
demonstrate that HER2 overexpression causes more rapid
wound closure under EGF treatment due to increases in
speed and persistence. However, in the absence of ligand or
under HRG treatment, changes in closure rates are due pri-
marily to increased cell persistence alone. HER2’s inﬂuence
on the effective diffusion of cells is found by equating Eq. 1
to 4 Dt when t  P, where D is the diffusion constant or
random motility coefﬁcient (as it is more often referred to in
migration literature). Expressing D as
D ¼ S2P=2; (2)
we can evaluate the net effect of changes in speed and per-
sistence on cell migration. Fig. 2 C shows that the diffusion
constant describes differences in the magnitude of migration
between conditions that are consistent with those observed
using the wound closure assay (Figs. 1 A and 2 C). Thus,
depending on the ligand treatment, the cell regulates speed
and persistence in qualitatively different ways to achieve
HER2-mediated increases in migration as measured by wound
closure or diffusion.
The biological regulators of directional movement are not
fully understood, but recent work has implicated Rac1,
microtubules, and myosin IIb as possible candidates (7–9).
Whatever the downstream regulators, our data indicate that
HER2 overexpression affects cellular components involved
with directional movement independently from those respon-
sible for increased cell speed. We speculate that differential
phosphorylation under the various ligand treatment and
receptor levels considered initiates downstream signaling
differences that affect cell speed and persistence differently.
Our data show, however, that under a variety of activating
conditions, HER2 overexpression increases cell persistence,
perhaps indicating the existence of a redundant phospho-site
or signaling mechanism responsible for increasing persis-
tence. This strong connection between HER2 and direction-
ally persistent migration may, in turn, be an important facet to
HER2’s documented ability to increase invasion and me-
tastasis in human breast cancer cells.
SUPPLEMENTARY MATERIAL
An online supplement to this article can be found by visiting
BJ Online at http://www.biophysj.org.
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FIGURE 2 HER2 effects on cell speed and persistence. Cell mi-
gration of parental and 24H cells treated with EGF (100 ng/ml), HRG
(80 ng/ml), or in serum-free conditionswas recorded and quantiﬁed
for (A) cell speed in mm/h, (B) directional persistence in minutes,
and (C) diffusion constant in mm2/h. D shows inequalities at 95%
conﬁdence as evaluated using Kolmogorov-Smirnov test for
nonnormal distributions. All data reported as mean 6 SE. Number
of cells per condition equals 153–196. (See Supplementary
Methods and Supplementary Fig. 4 for raw data histograms.)
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